Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Claim review
Thymosin Alpha-1 + LL-37 — claim review
Marketed as the headline 'immune optimisation stack' for long COVID, chronic infections, and 'immune ageing'. Thymosin Alpha-1 has genuine clinical evidence in specific licensed indications; LL-37 is essentially untested in humans. The combination has zero trial evidence and meaningful autoimmune-flare risk.
What people claim
- “Restores T-cell function in long COVID”
- “Treats chronic Lyme / mould / biofilm infections”
- “Reverses immune ageing”
Evidence honestly
Thymosin Alpha-1 has Phase 2-3 clinical trials in licensed indications (hepatitis B/C, immune adjuvant in cancer). Long COVID, general immunity, and autoimmune-overlap use have no Phase 3 evidence.
LL-37 has substantial preclinical antimicrobial-peptide data but essentially no human therapeutic use trials. The combination has not been formally studied.
Safer alternatives
- NHS long-COVID clinic referral via GP (availability varies regionally).
- NHS immunology pathway for suspected primary or secondary immunodeficiency.
- Vaccination per current UK schedule — the highest-evidence immune intervention.
Frequently asked questions
- Does this combination treat long COVID?
- Neither compound has Phase 3 RCT evidence for long COVID. Both are heavily marketed in long-COVID communities on mechanistic grounds. The combination has no specific trial.
- Is Thymosin Alpha-1 licensed?
- Yes — in 35+ countries (as Zadaxin) for chronic hepatitis B/C and as an immune adjuvant in certain cancer treatments. Not MHRA-licensed in the UK. UK access is non-NHS, unlicensed-medicine basis.
- Is LL-37 safe to combine with immune-modulators?
- LL-37 is pro-inflammatory in some contexts. Combining it with another immune-stimulant peptide is uncharacterised and may risk triggering or worsening autoimmune disease.
- What is the autoimmune-flare concern?
- Non-specific immune stimulation can worsen autoimmune disease. Anyone with diagnosed or suspected autoimmunity should be cautious; specialist immunology advice is essential before any immune-modulating compound.
- What is the lawful UK alternative for the symptoms this targets?
- GP review to rule out treatable causes, NHS long-COVID clinic referral where eligible, vaccination programmes for general immune support, immunology referral for suspected immunodeficiency.